XML 15 R10.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Shared-Based Payments | 9 Months Ended
--- | ---
Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Shared-Based Payments | 5. Shared-Based Payments Stock Option Plan The Company’s 2000 Stock Option and Incentive Plan (the 2000 Plan) allowed for the grant of awards in respect of an aggregate of 130,725 shares, which was increased to 150,297 shares, of the Company’s common stock in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and other performance awards. Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (the 2003 Plan), and it was amended and approved by the Company’s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company’s common stock. During the year ended December 31, 2006, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 460,746 shares to 2,512,390. During the year ended December 31, 2008, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 745,716 shares to 3,258,106. During the year ended December 31, 2010, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 532,654 shares to 3,790,760. During the year ended December 31, 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 545,970 shares to 4,336,731. As of September 30, 2013, a total of 8,171 shares were available for issuance under the 2003 Plan. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. The following stock-based compensation amounts were recognized for the periods indicated:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2013 |  |  | 2012 |  |  | 2013 |  |  | 2012 |
Research and development |  | $ | 111,888 |  |  | $ | 117,952 |  |  | $ | 284,281 |  |  | $ | 353,856 |
General and administrative |  |  | 24,048 |  |  |  | 91,647 |  |  |  | 109,280 |  |  |  | 274,940 |
Total stock-based compensation expense |  | $ | 135,936 |  |  | $ | 209,599 |  |  | $ | 393,561 |  |  | $ | 628,796 |
Employee Stock Options The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:
|  | Nine Months Ended September 30,
|  | 2013 |  | 2012
Expected dividend yield |  | 0% |  | 0%
Expected volatility |  | 53% - 58% |  | 51%
Risk-free interest rate |  | 1.24% - 2.05% |  | 1.18%
Expected average life of options |  | 7 years |  | 7 years
Fair market value of common stock at: |  | $1.50 - $7.51 |  | $1.50
Expected forfeiture rate |  | 5.06% |  | 5.57%
Fair Value of Common Stock – Before our entry into the public market on October 10, 2013, the Company’s Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. In the absence of a public market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. The factors include: (1) the achievement of clinical and operational milestones by the Company; (2) the status of strategic relationships with collaborators; (3) the significant risks associated with the Company’s stage of development; (4) capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (5) the Company’s available cash, financial condition and results of operations; (6) the most recent sales of the Company’s preferred stock and (7) the preferential rights of the outstanding preferred stock. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled Valuation of Privately-Held Company Equity Securities Issued as Compensation. Expected Volatility – Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not maintain an internal market for its shares and its shares are not traded publicly. The Company has been able to identify several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of these companies. Expected Dividend Yield – The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. Risk-Free Interest Rate – This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. Expected Term – This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be seven years. The Company uses a simplified method to calculate the average expected term. Expected Forfeiture Rate – The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted. Equity instruments issued to non-employees are accounted for under the provisions of ASC 505-50, Equity Based Payments to Non-Employees. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services required are completed. The following table summarizes stock option activity under the Plan during the period then ended:
|  | Number of Options |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Contractual Term (in Years) |
Outstanding, December 31, 2012 |  |  | 3,249,702 |  |  |  | 0.94 |  |  |  | 7.3 |
Granted |  |  | 687,183 |  |  |  | 3.19 |  |  |  | 7.0 |
Exercised |  |  | (1,025,933 | ) |  |  | 0.75 |  |  |  |  |
Forfeited or expired |  |  | (33,949 | ) |  |  | 1.13 |  |  |  |  |
Outstanding, September 30, 2013 |  |  | 2,877,003 |  |  |  | 1.50 |  |  |  | 7.2 |
September 30, 2013: |  |  |  |  |  |  |  |  |  |  |  |
Exercisable |  |  | 1,855,178 |  |  |  | 0.94 |  |  |  |  |
Vested and Expected to Vest |  |  | 918,600 |  |  |  | 2.44 |  |  |  |  |
The aggregate intrinsic value of options outstanding and options exercisable as of September 30, 2013 is approximately $17.4 million and $12.2 million, respectively. The weighted-average grant-date fair value of options granted for the nine months ended September 30, 2013 was $2.00. Total cash received for the options exercised was $851,183 for the nine months ended September 30, 2013. The total fair value of shares vested in the nine months ended September 30, 2013 was $402,084. As of September 30, 2013, the total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the 2000 Plan and 2003 Plan, net of related forfeiture estimates, was $1.5 million, which the Company expects to recognize over a weighted-average period of approximately four years.

X
- Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration